^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BNT151
i
Other names: BNT151 , BNT 151, BNT-151
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BioNTech
Drug class:
IL-2 stimulant
Related drugs:
6ms
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (clinicaltrials.gov)
P1/2, N=62, Terminated, BioNTech SE | Active, not recruiting --> Terminated; Sponsor decision
Trial termination • Combination therapy
|
BNT151
9ms
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (clinicaltrials.gov)
P1/2, N=84, Active, not recruiting, BioNTech SE | Trial completion date: Jun 2026 --> May 2024 | Trial primary completion date: Feb 2024 --> May 2024
Trial completion date • Trial primary completion date • Combination therapy
|
BNT151
1year
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (clinicaltrials.gov)
P1/2, N=84, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
BNT151
over3years
[VIRTUAL] An RNA-encoded IL-2 variant with an extended half-life mediates synergistic anti-tumor activity when combined with immune checkpoint blockade (CIMT 2021)
Tumor control of the combination treatment was accompanied by increased numbers of neoantigen-specific T cells and a T cell phenotype previously associated with successful cancer immunotherapy. An open-label, Phase I/II, first-in-human trial in patients with advanced solid tumors was recently initiated to further explore the clinical safety and efficacy of BNT151 as monotherapy or in combination with other anti-cancer agents (NCT04455620).
Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
IL2-L
|
BNT151
Share via
